Entities / Company
Johnson & Johnson.
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- Reports this week
- 7
- Active events
- 8
- Connections
- 603
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.Well supported5 reports
-
Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.Well supported4 reports
-
Microsoft and Alphabet are funding the AI boom, while TRACE pricing data is used for bond comparisons and both companies hold AAA ratings.Well supported4 reports
-
Gardiner Harris's investigative reporting led to fraud fines against Bristol-Myers Squibb and a book dissecting Johnson & Johnson scandals.Some support1 report
-
Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.Some support1 report
-
Johnson & Johnson operates a business unit focused on surgical and orthopedic equipment.Some support1 report
-
Orthopaedics separation is expected to reshape Johnson & Johnson's MedTech segment.Some support1 report
-
Procter & Gamble, Johnson & Johnson, Coca-Cola, and Verizon are discussed as income-generating companies referenced in dividend investment strategies.Some support5 reports2 developments inside
Earlier this month
-
MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Some support2 reports1 development inside
-
CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.Some support1 report
-
Johnson & Johnson, Carl Zeiss, and Bausch Health are major players in the vision care market, supported by supportive government initiatives.Some support2 reports4 developments inside
-
Nvidia, Coca-Cola, and Johnson & Johnson are being discussed together in the context of investment trends.Some support1 report
-
Coca-Cola and Johnson & Johnson announced dividend raises, while SmartAsset continues to assist users with retirement planning.Some support3 reports
-
UK approved Johnson & Johnson's oral psoriasis treatment, and Amundi increased its holdings in J&J shares.Some support1 report
-
AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.Some support1 report1 development inside
-
The UK approved Johnson & Johnson's oral treatment for psoriasis.Some support1 report
-
Amundi increased its stake in Johnson & Johnson, while Bank of America, Morgan Stanley, and TD Cowen issued rating and price target updates on the company.Some support2 reports
-
Johnson & Johnson and Mastercard are currently top holdings within the JEPI investment fund.Some support3 reports
-
Johnson & Johnson and Broadcom are noted as major holdings in the same investment fund, which also involves Apollo Global Management.Some support1 report
-
Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.Some support1 report1 development inside
-
Johnson & Johnson joins the USMN initiative.Some support1 report
-
Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.Well supported6 reports4 developments inside
-
Johnson & Johnson was referenced in a recent news report concerning New York City.Some support1 report
-
Janssen Research & Development was located in Beerse on October 21, 2026.Some support1 report
-
Failures resulted in catastrophic reputational damage for several major companies, while others successfully used safety as a brand differentiator.Some support1 report
-
AppLovin fears being in Alphabet's crosshairs, while Compass Pathways avoids Johnson & Johnson due to size.Some support1 report
-
Dividend yields for companies like P&G and J&J are benchmarked against Fed targets, serving investors needing financial advice.Some support4 reports
-
Johnson & Johnson reports mixed sales performance for several key drugs, with Imbruvica and Remicade declining while Darzalex and Tremfya show strong sales.Some support1 report
-
Ben-Zvi worked on campaigns for Johnson & Johnson while overseeing the iProspect business at Dentsu.Some support1 report
-
Johnson & Johnson filed recent stock holdings with the SEC on October 15, 2026.Some support1 report
-
Johnson & Johnson successfully spun off Kenvue to focus on core business, while FED policy signals affect market perception of JNJ.Well supported5 reports4 developments inside
-
Johnson & Johnson's MedTech segment reported sales below expectations and is facing an investigation into federal securities law violations.Some support2 reports
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported5 reports2 developments inside
-
Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Some support1 report
-
Johnson & Johnson MedTech is facing multiple headwinds from China procurement changes, Middle East disruptions, and AbioMed weakness.Some support1 report
-
Conflict in the Middle East impacted sales for Johnson & Johnson.Some support1 report
-
Bank stocks fell on mixed Q3 results, while Johnson & Johnson reported better-than-expected pharma results.Some support2 reports
-
Johnson & Johnson presented clinical data at the American College of Gastroenterology meeting.Some support1 report
-
The FDA approved a new device manufactured by Cordis, a company with a complex history of corporate acquisitions.Some support1 report
-
Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.Some support1 report
-
Johnson & Johnson and TreasuryDirect are competing for investor capital streams.Some support1 report
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
A global study was conducted on menopausal women's health, alongside collaborations to raise eye health awareness and accept AI regulation recommendations.Some support1 report
One to three months ago
-
Cramer suggested both Coca-Cola and Johnson & Johnson as stocks to buy due to stability in a weak economy.Some support1 report
-
Johnson & Johnson highlights its oncology pipeline as a key growth driver.Some support1 report
-
Johnson & Johnson and Bank of America Merrill Lynch participated in the Q3 earnings season on October 7, 2026.Some support1 report
-
On October 7, 2026, Timothy Schmid and Jennifer Taubert sold Johnson & Johnson shares, while Cooper Financial Group boosted its position.Some support2 reports
-
Lloyd Doggett purchased shares of IBM, Johnson & Johnson, Procter & Gamble, and PPG Industries on October 7, 2026.Some support2 reports
-
MarketBeat listed Johnson & Johnson, Medtronic plc, and Eli Lilly and Company as top healthcare stocks on October 7, 2026.Some support2 reports
-
Analyst targets are being lowered amid new entrants challenging market dominance for medical technology companies.Some support1 report1 development inside
-
Jim Cramer advised against Intuitive Surgical stock, citing competition from Johnson & Johnson.Some support2 reports
-
A fund trimmed its position in Johnson & Johnson (JNJ) stock and disclosed the transaction via financial filings with the SEC.Some support3 reports
-
Investigative reporting exposed a pattern of lies involving Larry Foster and Johnson & Johnson.Some support1 report
-
Survey results were presented in Anaheim, CA, by the Director of global medical education at Johnson & Johnson.Some support1 report
-
HSBC provided a buy rating and price target for Johnson & Johnson, while Morgan Stanley raised its price objective to $294.00. The company also filed required 13F reports with the SEC.Some support2 reports
-
P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Well supported11 reports
-
Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Well supported18 reports
-
Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.Well supported14 reports1 development inside
-
Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.Some support1 report
-
The CBO reported an $8.8 billion handout in OBBB, which weakened Medicare drug price negotiation. Bryan Steil voted for the bill benefiting Big Pharma, after receiving donations from lobbyists.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Johnson & Johnson
Events traced to Johnson & Johnson, step by step, newest first- Competitor analysis sets benchmark for Johnson & Johnson's stabilityJohnson & Johnson's investment profile is benchmarked against competitor financial resilience.Possible
- Indian vaccine capacity may intensify competition for Johnson & JohnsonIncreased Indian vaccine capacity may intensify competition for Johnson & JohnsonPossible
- Merck's expanding pipeline may intensify competition for Johnson & JohnsonMerck's pipeline growth could increase competitive pressure on Johnson & JohnsonPossible
- Moderna's new cancer vaccine platform may intensify competition for Johnson & JohnsonModerna's new cancer vaccine platform may intensify competition for Johnson & JohnsonPossible
- AbbVie's new immunology drug may intensify competition with Johnson & JohnsonAbbVie's new drug may intensify competition with Johnson & JohnsonPossible
- How could Abbott Laboratories' nutrition business separation affect Johnson & Johnson?Abbott's nutrition separation changes competitive landscape for J&JPossible
See all 15 explainers
- Genmab's expanded collaborations may boost Johnson & Johnson's revenueGenmab's strengthened pipeline may boost Johnson & Johnson's royalty revenuePossible
- Medtronic's surgical robot entry increases competition for Johnson & JohnsonMedtronic's surgical robot entry increases competition for Johnson & JohnsonPossible
- Medtech's 4.8% U.S. growth supports Johnson & Johnson's revenueMedtech's 4.8% U.S. growth supports Johnson & Johnson's overall revenue outlookAlready happening
- P&G's growth risks may shift investor focus toward Johnson & JohnsonP&G's growth risks may shift investor focus toward Johnson & JohnsonPossible
- Intuitive Surgical's strong margins may increase competitive pressure on Johnson & JohnsonIntuitive Surgical's growth may increase competitive pressure on Johnson & JohnsonPossible
- How could high I Bond rates affect Johnson & Johnson's investment appeal?High I Bond rates may draw investor capital away from stocksPossible
- Johnson & Johnson may face reputational and financial risk from Abiomed's kickback fineJohnson & Johnson may face reputational and financial risk from Abiomed's kickback finePossible
- Johnson & Johnson's drug pricing faces federal price capsJ&J's drug revenue may face limits due to IRA price negotiationLikely
- BirlaSoft's AI solutions could disrupt Johnson & Johnson's MedTech operationsBirlaSoft's AI deployment may challenge Johnson & Johnson's MedTech workflowsPossible
Explainers that pass through Johnson & Johnson
Johnson & Johnson is a step on the way to someone elseAround Johnson & Johnson this week
News at the entities that move Johnson & Johnson most-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Johnson & Johnson
-
Eli Lilly and Company OperationalTrade data and legislative control are currently influencing market sentiment and corporate operations.Moves Johnson & Johnson
-
SEC StructuralDirector Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Moves Johnson & Johnson
-
Donald Trump OperationalNPR investigated a detention plan implemented by the Trump administration, involving DHS policy officials.Moves Johnson & Johnson
-
FED OperationalTrump's party lost the midterms, Democrats gained Congress, and Fed officials consulted a Boston College economist.Moves Johnson & Johnson
-
Berkshire Hathaway StructuralUnder Greg Abel's leadership, Berkshire Hathaway has made major strategic moves, including acquiring Taylor Morrison and making a private placement in Alphabet.Moves Johnson & Johnson
Connections
The 40 strongest of 603, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Berkshire Hathaway Structural
Berkshire Hathaway historically owned Johnson & Johnson.
-
Eli Lilly and Company Operational
The two pharmaceutical giants are engaged in intense, direct market competition across various therapeutic and growth segments.
-
Legend Biotech Structural
Legend Biotech and Johnson & Johnson maintain a deep structural partnership, co-developing and supplying the CARVYKTI treatment, cemented by J&J's investment in Legend's portfolio.
-
Joaquin Duato Structural
Joaquin Duato serves as the Chairman and CEO of Johnson & Johnson, leading the company's operations and strategy.
-
SEC Structural
Johnson & Johnson is subject to mandatory financial and disclosure regulations enforced by the SEC.
-
Kenvue Structural
Kenvue was formed as a spin-off of Johnson & Johnson's consumer health business unit.
-
Medtech Structural
Medtech operates as a core business segment and subsidiary within Johnson & Johnson's corporate structure.
-
AbioMed Structural
Johnson & Johnson owns AbioMed as a subsidiary, and AbioMed's operational performance impacts J&J's growth.
Show all 40 connections
-
Howard Reid Structural
Howard Reid serves as the VP of corporate brand at Johnson & Johnson.
-
Jim Cramer Operational
Jim Cramer provides investment commentary and recommendations regarding Johnson & Johnson's stock performance and business health.
-
Zymeworks Structural
Johnson & Johnson utilizes Zymeworks' proprietary technology platform for the development and production of clinical-stage antibodies.
-
CORDIS Structural
Johnson & Johnson acquired Cordis in 1996, establishing Cordis as a subsidiary.
-
Genmab Structural
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement.
-
Procter & Gamble Operational
Both companies are direct competitors in the consumer staples market, frequently compared based on dividend growth and financial resilience.
-
Intuitive Surgical Operational
Intuitive Surgical and Johnson & Johnson are active market rivals competing for dominance in the surgical robotics and minimally invasive medical device sectors.
-
Amundi Transactional
Amundi repeatedly increased its investment holdings and stake in Johnson & Johnson shares throughout 2026.
-
FDA Structural
The FDA functions as the mandatory regulatory gatekeeper, evaluating and granting market access approvals for Johnson & Johnson's medical and pharmaceutical products.
-
HAAS Structural
Erik Haas serves as the Vice President of Litigation for Johnson & Johnson.
-
Vanguard Structural
Vanguard holds shares of Johnson & Johnson as part of its investment portfolio.
-
Pfizer Operational
Pfizer and Johnson & Johnson are major pharmaceutical competitors operating in shared markets, facing common industry pressures and competing for investment capital.
-
AbbVie Operational
AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.
-
Merck Operational
Johnson & Johnson and Merck are major pharmaceutical companies actively competing for market share in specialized drug sectors like oncology and PAH.
-
Abbott Laboratories Operational
Both companies are major healthcare giants that actively compete for market share through product innovation and strategic moves.
-
Janssen Biotech Structural
Janssen Biotech operates as a licensed entity under Johnson & Johnson.
-
Boston Scientific Operational
Both companies are major competitors in the medical device and endoscopy markets.
-
Donald Trump Operational
Trump's political policies and tariff threats significantly influence J&J's operational strategy and market outlook, while J&J is also referenced in Trump's financial disclosures.
-
Idorsia Transactional
Idorsia was acquired by Johnson & Johnson, leading to its subsequent spin-off.
-
Daiwa Securities Group Operational
Daiwa Securities Group actively influences Johnson & Johnson's market valuation through analyst reports and price target adjustments.
-
Viswanathan Transactional
Viswanathan previously held a sales and marketing role at Johnson & Johnson.
-
FED Operational
FED's monetary policy and economic signals actively influence Johnson & Johnson's market perception and valuation.
-
Jacksonville Structural
Johnson & Johnson is expanding its U.S. Vision manufacturing operations in Jacksonville with a $1 billion investment.
-
AC Immune Structural
AC Immune collaborates with Johnson & Johnson on drug evaluation, with milestone payments triggered by trial progress.
-
Protagonist Therapeutics (United States) Structural
Protagonist Therapeutics and Johnson & Johnson maintain a strategic partnership involving the joint development and licensing of the drug Icotrokinra.
-
Acuvue Structural
Johnson & Johnson operates and launches products under the Acuvue brand.
-
Morgan Stanley Operational
Morgan Stanley provides financial analysis and price targets for Johnson & Johnson shares, and J&J participates in MS events.
-
Meredith Bishop Structural
Meredith Bishop serves as the Director of global medical education at Johnson & Johnson.
-
John Reed Structural
John Reed serves as an Executive Vice President at Johnson & Johnson and is a member of the Executive Committee.
-
SPDR Structural
SPDR ETF holds Johnson & Johnson as a major investment position, representing a formal ownership stake.
-
company Structural
Johnson & Johnson maintains a structural dependency on the entity 'company' through receiving royalties from a collaboration.
-
Tom Cavanaugh Structural
Forecasted leadership role of Tom Cavanaugh within the Innovative Medicine division of Johnson & Johnson.
History
Events by the month they beganNovember 2026
4 events- Gardiner Harris's investigative reporting led to fraud fines against Bristol-Myers Squibb and a book dissecting Johnson & Johnson scandals.
- Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.
- Johnson & Johnson operates a business unit focused on surgical and orthopedic equipment.
- Orthopaedics separation is expected to reshape Johnson & Johnson's MedTech segment.
October 2026
36 events- Microsoft and Alphabet are funding the AI boom, while TRACE pricing data is used for bond comparisons and both companies hold AAA ratings.
- MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.
- CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.
- Nvidia, Coca-Cola, and Johnson & Johnson are being discussed together in the context of investment trends.
- UK approved Johnson & Johnson's oral psoriasis treatment, and Amundi increased its holdings in J&J shares.
- The UK approved Johnson & Johnson's oral treatment for psoriasis.
- Amundi increased its stake in Johnson & Johnson, while Bank of America, Morgan Stanley, and TD Cowen issued rating and price target updates on the company.
- Johnson & Johnson and Broadcom are noted as major holdings in the same investment fund, which also involves Apollo Global Management.
- Johnson & Johnson joins the USMN initiative.
- Johnson & Johnson was referenced in a recent news report concerning New York City.
- Janssen Research & Development was located in Beerse on October 21, 2026.
- Failures resulted in catastrophic reputational damage for several major companies, while others successfully used safety as a brand differentiator.
- AppLovin fears being in Alphabet's crosshairs, while Compass Pathways avoids Johnson & Johnson due to size.
- Johnson & Johnson reports mixed sales performance for several key drugs, with Imbruvica and Remicade declining while Darzalex and Tremfya show strong sales.
- Ben-Zvi worked on campaigns for Johnson & Johnson while overseeing the iProspect business at Dentsu.
- Johnson & Johnson filed recent stock holdings with the SEC on October 15, 2026.
- Johnson & Johnson's MedTech segment reported sales below expectations and is facing an investigation into federal securities law violations.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
- Johnson & Johnson MedTech is facing multiple headwinds from China procurement changes, Middle East disruptions, and AbioMed weakness.
- Conflict in the Middle East impacted sales for Johnson & Johnson.
- Bank stocks fell on mixed Q3 results, while Johnson & Johnson reported better-than-expected pharma results.
- Johnson & Johnson presented clinical data at the American College of Gastroenterology meeting.
- The FDA approved a new device manufactured by Cordis, a company with a complex history of corporate acquisitions.
- Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.
- Johnson & Johnson and TreasuryDirect are competing for investor capital streams.
- Major pharmaceutical companies are competing for investment capital.
- A global study was conducted on menopausal women's health, alongside collaborations to raise eye health awareness and accept AI regulation recommendations.
- Cramer suggested both Coca-Cola and Johnson & Johnson as stocks to buy due to stability in a weak economy.
- Johnson & Johnson highlights its oncology pipeline as a key growth driver.
- Johnson & Johnson and Bank of America Merrill Lynch participated in the Q3 earnings season on October 7, 2026.
- On October 7, 2026, Timothy Schmid and Jennifer Taubert sold Johnson & Johnson shares, while Cooper Financial Group boosted its position.
- Lloyd Doggett purchased shares of IBM, Johnson & Johnson, Procter & Gamble, and PPG Industries on October 7, 2026.
- MarketBeat listed Johnson & Johnson, Medtronic plc, and Eli Lilly and Company as top healthcare stocks on October 7, 2026.
- Jim Cramer advised against Intuitive Surgical stock, citing competition from Johnson & Johnson.
- Investigative reporting exposed a pattern of lies involving Larry Foster and Johnson & Johnson.
- Survey results were presented in Anaheim, CA, by the Director of global medical education at Johnson & Johnson.
September 2026
5 events- Johnson & Johnson and Mastercard are currently top holdings within the JEPI investment fund.
- Dividend yields for companies like P&G and J&J are benchmarked against Fed targets, serving investors needing financial advice.
- HSBC provided a buy rating and price target for Johnson & Johnson, while Morgan Stanley raised its price objective to $294.00. The company also filed required 13F reports with the SEC.
- Healthcare architecture is rapidly changing, with robotic procedures underway in Riyadh involving major players like Johnson & Johnson, Mayo Clinic, and Cleveland Clinic.
- The CBO reported an $8.8 billion handout in OBBB, which weakened Medicare drug price negotiation. Bryan Steil voted for the bill benefiting Big Pharma, after receiving donations from lobbyists.
Show 3 earlier months
August 2026
3 events- Procter & Gamble, Johnson & Johnson, Coca-Cola, and Verizon are discussed as income-generating companies referenced in dividend investment strategies.
- Coca-Cola and Johnson & Johnson announced dividend raises, while SmartAsset continues to assist users with retirement planning.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
July 2026
2 eventsJune 2026
10 events- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
- Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.
- Johnson & Johnson, Carl Zeiss, and Bausch Health are major players in the vision care market, supported by supportive government initiatives.
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
- Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.
- Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.
- Johnson & Johnson successfully spun off Kenvue to focus on core business, while FED policy signals affect market perception of JNJ.
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.
- Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.